195 related articles for article (PubMed ID: 27829249)
1. DcR3, TFF3, and Midkine Are Novel Serum Biomarkers in Small Intestinal Neuroendocrine Tumors.
Edfeldt K; Daskalakis K; Bäcklin C; Norlén O; Tiensuu Janson E; Westin G; Hellman P; Stålberg P
Neuroendocrinology; 2017; 105(2):170-181. PubMed ID: 27829249
[TBL] [Abstract][Full Text] [Related]
2. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors.
Khan TM; Garg M; Warner RR; Uhr JH; Divino CM
Pancreas; 2016 Aug; 45(7):1032-5. PubMed ID: 26684860
[TBL] [Abstract][Full Text] [Related]
3. Decoy receptor 3 (DcR3) overexpression predicts the prognosis and pN2 in pancreatic head carcinoma.
Zhou J; Song S; Li D; He S; Zhang B; Wang Z; Zhu X
World J Surg Oncol; 2014 Mar; 12():52. PubMed ID: 24597666
[TBL] [Abstract][Full Text] [Related]
4. Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.
Cui T; Hurtig M; Elgue G; Li SC; Veronesi G; Essaghir A; Demoulin JB; Pelosi G; Alimohammadi M; Öberg K; Giandomenico V
PLoS One; 2010 Dec; 5(12):e16010. PubMed ID: 21209860
[TBL] [Abstract][Full Text] [Related]
5. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients.
Yang M; Chen G; Dang Y; Luo D
Ups J Med Sci; 2010 Nov; 115(4):232-7. PubMed ID: 20977315
[TBL] [Abstract][Full Text] [Related]
6. Serum TFF1 and TFF3 but not TFF2 are higher in women with breast cancer than in women without breast cancer.
Ishibashi Y; Ohtsu H; Ikemura M; Kikuchi Y; Niwa T; Nishioka K; Uchida Y; Miura H; Aikou S; Gunji T; Matsuhashi N; Ohmoto Y; Sasaki T; Seto Y; Ogawa T; Tada K; Nomura S
Sci Rep; 2017 Jul; 7(1):4846. PubMed ID: 28687783
[TBL] [Abstract][Full Text] [Related]
7. Serum decoy receptor 3 is a biomarker for disease severity in nonatopic asthma patients.
Chen MH; Kan HT; Liu CY; Yu WK; Lee SS; Wang JH; Hsieh SL
J Formos Med Assoc; 2017 Jan; 116(1):49-56. PubMed ID: 26911723
[TBL] [Abstract][Full Text] [Related]
8. Decoy receptor 3 is a prognostic factor in renal cell cancer.
Macher-Goeppinger S; Aulmann S; Wagener N; Funke B; Tagscherer KE; Haferkamp A; Hohenfellner M; Kim S; Autschbach F; Schirmacher P; Roth W
Neoplasia; 2008 Oct; 10(10):1049-56. PubMed ID: 18813347
[TBL] [Abstract][Full Text] [Related]
9. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
11. Serum decoy receptor 3 (DcR3): a promising biomarker for atopic asthma in children.
Kamal A; Abdelmegeid AK; Gabr MAM; Basanti CWS
Immunol Res; 2021 Dec; 69(6):568-575. PubMed ID: 34383195
[TBL] [Abstract][Full Text] [Related]
12. Differential Protein Expression in Small Intestinal Neuroendocrine Tumors and Liver Metastases.
Kim MK; Ye F; Wang D; Cui M; Ward SC; Warner RR; Roayaie S; Shafir M; Schwartz M; Zhang D; Itzkowitz S
Pancreas; 2016 Apr; 45(4):528-32. PubMed ID: 26474427
[TBL] [Abstract][Full Text] [Related]
13. Functional characterisation of decoy receptor 3 in Crohn's disease.
Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
[TBL] [Abstract][Full Text] [Related]
14. [Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma].
Chen G; Luo DZ; Wang Y; Liao ZL; Zhang MY
Zhonghua Bing Li Xue Za Zhi; 2007 Feb; 36(2):113-7. PubMed ID: 17493386
[TBL] [Abstract][Full Text] [Related]
15.
Daskalakis K; Norlén O; Karakatsanis A; Hellman P; Larsson R; Nygren P; Stålberg P
Endocr Relat Cancer; 2018 Apr; 25(4):471-480. PubMed ID: 29440231
[TBL] [Abstract][Full Text] [Related]
16. Expression and Clinical Significance of Decoy Receptor 3 in Acute-on-Chronic Liver Failure.
Lin S; Wu B; Lin Y; Wang M; Zhu Y; Jiang J; Zhang L; Lin J
Biomed Res Int; 2019; 2019():9145736. PubMed ID: 31317042
[TBL] [Abstract][Full Text] [Related]
17. Serum decoy receptor 3 levels are associated with the disease activity of MPO-ANCA-associated renal vasculitis.
Maruyama H; Hirayama K; Nagai M; Ebihara I; Shimohata H; Kobayashi M
Clin Rheumatol; 2016 Oct; 35(10):2469-76. PubMed ID: 27251675
[TBL] [Abstract][Full Text] [Related]
18. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
[TBL] [Abstract][Full Text] [Related]
20. A single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs).
Tellez MR; Mamikunian G; O'Dorisio TM; Vinik AI; Woltering EA
Pancreas; 2013 Apr; 42(3):405-10. PubMed ID: 23160483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
